| Literature DB >> 30689374 |
Fengfei Wang1,2,3,4, Shuang Zhou1,2,5, Dan Qi1,2, Shi-Hua Xiang6, Eric T Wong5, Xuejing Wang7, Ekokobe Fonkem1,2,3,4,8, Tze-Chen Hsieh9, Jianhua Yang10, Batool Kirmani3,4, John B Shabb11, Joseph M Wu9, Min Wu11, Jason H Huang1,2,4, Wei-Hsuan Yu12, Erxi Wu1,2,4,8,13.
Abstract
The aim of this study is to illuminate a novel therapeutic approach by identifying a functional binding target of salinomycin, an emerging anticancer stem cell (CSC) agent, and to help dissect the underlying action mechanisms. By utilizing integrated strategies, we identify that nucleolin (NCL) is likely a salinomycin-binding target and a critical regulator involved in human neuroblastoma (NB) CSC activity. Salinomycin markedly suppresses NB CD34 expression and reduces CD34+ cell population in an NCL-dependent manner via disruption of the interaction of NCL with CD34 promoter. The elevated levels of NCL expression in NB tumors are associated with poor patient survival. Altogether, these results indicate that NCL is likely a novel functional salinomycin-binding target that exhibits the potential to be a prognostic marker for NB therapy.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30689374 DOI： 10.1021/jacs.8b12872
Source DB: PubMed Journal: J Am Chem Soc ISSN： 0002-7863 Impact factor: 15.419